Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

impexeco - ethinylestradiol betadex clathrate; drospirenone - film-coated tablet - 0,02 mg - 3 mg - ethinylestradiol betadex clathrate; drospirenone 3 mg - drospirenone and ethinylestradiol

Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - ethinylestradiol betadex clathrate - eq. ethinylestradiol 0,02 mg; drospirenone 3 mg - film-coated tablet - 0,02 mg - 3 mg - ethinylestradiol betadex clathrate; drospirenone 3 mg - drospirenone and ethinylestradiol

Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

impexeco - ethinylestradiol betadex clathrate; drospirenone - film-coated tablet - 0,02 mg - 3 mg - ethinylestradiol betadex clathrate; drospirenone 3 mg - drospirenone and ethinylestradiol

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - letermovir, quantity: 480 mg - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydroxypropylbetadex - prevymis is indicated for the prophylaxis of cytomegalovirus (cmv) infection or disease in adult cmv-seropositive recipients [r+] of an allogeneic hematopoietic stem cell transplant (hsct).

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - letermovir, quantity: 240 mg - injection, concentrated - excipient ingredients: water for injections; hydroxypropylbetadex; sodium chloride; sodium hydroxide - prevymis is indicated for the prophylaxis of cytomegalovirus (cmv) infection or disease in adult cmv-seropositive recipients [r+] of an allogeneic hematopoietic stem cell transplant (hsct).

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - ad26.cov2.s, quantity: 50000000000 vp - injection, suspension - excipient ingredients: sodium chloride; polysorbate 80; sodium hydroxide; hydroxypropylbetadex; citric acid monohydrate; sodium citrate dihydrate; ethanol absolute; hydrochloric acid; water for injections - covid-19 vaccine janssen has provisional approval for the indication:,covid-19 vaccine janssen is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older.,the use of this vaccine should be in accordance with official recommendations. the decision has been made on the basis of short term efficacy and safety data. continued approval is dependent upon the evidence of longer-term efficacy and safety from ongoing clinical trials and post-market assessment.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: sulfobutyl betadex sodium - vfend is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. *prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - posaconazole 18 mg/ml;   - concentrate for injection - 300mg/16.7ml - active: posaconazole 18 mg/ml   excipient: disodium edetate hydrochloric acid sodium hydroxide sulfobutyl betadex sodium water for injection - noxafil (posaconazole) concentrated injection is indicated for use in the treatment of the following invasive fungal infections in adults: - invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. - fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. noxafil is also indicated for the: - prophylaxis of invasive fungal infections among adults, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

chiesi limited - piroxicam betadex - tablets - 20mg milligram

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - voriconazole 200mg;  ;   - powder for injection - 200 mg - active: voriconazole 200mg     excipient: sulfobutyl betadex sodium water for injection - vfend is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida sp. infections (including c. krusei), including oesophageal and systemic candida sp. infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.